Moderna plans Omicron-specific booster shot by August - Reuters
Maddie Meyer/Getty Images News


Moderna's (NASDAQ:MRNA) Omicron-specific booster shot could be ready by August, Reuters reported citing company CEO StÃ©phane Bancel.
However, the company is still collecting data to know if the vaccine will offer better protection than a new dose of the existing shot.

In January, Moderna (MRNA) began dosing in a phase 2 trial evaluating an Omicron-specific COVID-19 vaccine. The company also reported pre-clinal data that suggested that the Omicron-specific shot may not offer stronger protection than a new dose of the current shot.
Bancel told Reuters that the company believes a booster would be needed but as of now does not know if it would be the existing vaccine, Omicron-only, or bivalent: Omicron and existing vaccine, two mRNA in one dose.
The company also expects to have a pan-vaccine âoffering protection against COVID-19, flu and other respiratory diseases â ready by by August 2023, in a best case scenario, the report added citing Bancel.
MRNA -0.99% pre-market to $150.30